Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: A network meta-analysis (Chongqing, China)
Menopause Aug 06, 2019
Tan X, et al. - Different pharmacological agents, including abaloparatide and romosozumab, for treatment of osteoporosis in postmenopausal women, were compared regarding their effectiveness and safety. Searching PubMed, Embase, the Cochrane Central Register of Controlled Trials, and Google Scholar, researchers identified 21 records for inclusion in quantitative synthesis; all of these records were of high quality. The analysis suggests that for preventing new vertebral and nonvertebral fractures in postmenopausal women with osteoporosis, abaloparatide and teriparatide were most efficacious, whereas in preventing clinical fractures, zoledronic acid and romosozumab were most efficacious. In terms of safety, abaloparatide, teriparatide or romosozumab, and placebo had no statistical differences. Moreover, in terms of adverse events, statistically worse outcomes were reported in correlation with zoledronic acid vs placebo, and denosumab and romosozumab were reported to be the two of the best interventions, of which denosumab also reduces the risk of different kinds of fractures.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries